Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2018 8:31:20 GMT -5
Here is a breakdown of MannKind's commitments through 2023:
2018 $30,800,000
2019 $45,450,000
2020 $19,000,000
2021 $122,356,000
2022 $23,700,000
2023 $23,700,000
|
|
|
|
Post by uvula on Jan 27, 2018 8:40:43 GMT -5
What is the 2021 commitment? It's huge.
|
|
|
|
Post by agedhippie on Jan 27, 2018 10:58:23 GMT -5
What is the 2021 commitment? It's huge. The Mann Group debt, and the 2021 Notes fall due. That's $79 million and $23 million respectively. There are also milestone payments out there still I think but it's harder to assess when they hit because they are sales based with the first one at $50M and then every $50M in sales until $400M in sales. Each milestone is worth $5M. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2018 12:52:06 GMT -5
First up $2.7 million due to Amphastar in March.
|
|
|
|
Post by falconquest on Jan 27, 2018 16:12:08 GMT -5
Here is a breakdown of MannKind's commitments through 2023: 2018 $30,800,000 2019 $45,450,000 2020 $19,000,000 2021 $122,356,000 2022 $23,700,000 2023 $23,700,000 Good info. Kastanes. Kinda like having a glass of cold water thrown in one's face isn't it? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2018 16:32:19 GMT -5
These commitments and a lack of a partnership with substantial up-front cash is preventing MannKind stock from appreciating. This has been something I have fretted about since buying into the potential of Afrezza.
|
|
|
|
Post by dreamboatcruise on Jan 27, 2018 18:58:58 GMT -5
Even if one believes progress will create enough confidence that equity financing will be possible, the magnitude of the resulting dilution would be quite hard to bound.
|
|
|
|
Post by pantaloons on Jan 27, 2018 21:02:33 GMT -5
Even if one believes progress will create enough confidence that equity financing will be possible, the magnitude of the resulting dilution would be quite hard to bound. How far in advance do you suspect MNKD will need to raise funds in order to extend their runway from 2nd quarter of 2018 onward? I assume it will need to be very soon and I'm not certain if progress on that aspect will necessarily be announced at the upcoming NobelCon14 meeting. Whenever it is, it would be best if it followed either 1) major news that will increase the PPS enough to make dilution more palatable or 2) upfront money from a partnership. My concern is that neither of these will transpire and dilution at around current PPS levels will be necessary. Perhaps the most ideal time for scenario 2 to have occurred is likely around the time of the FDA label change. Therefore, I think scenario 1 is the more likely path to further funding at this time, however what exactly that will entail is unknown. The consensus is that the STAT study results won't be released until the ADA meeting, which would be too late. The only other major catalyst that I can think of is a significant improvement in insurance coverage and/or increase in script #'s. MNKD seems to have less influence on improving insurance coverage. On the other hand, if it's true that script #'s should benefit 3-6 months following the launch of the new commercialization efforts (TV ads) in Q4 of 2017, then we should start to see an increase in script #'s right around the time when the company will definitely need to raise more capital. What are your thoughts on this? |
|
|
|
Post by mannmade on Jan 27, 2018 21:41:41 GMT -5
Could also be announcement of IND filing for pulmonary hypertension drug.
|
|
|
|
Post by dreamboatcruise on Jan 27, 2018 21:46:04 GMT -5
Could also be announcement of IND filing for pulmonary hypertension drug. Do you think that would really be perceived as a significant event? Management has said they are doing it, and it isn't something that gives any additional insight about likelihood of approval... it's just a necessary step in the process that we already know is in the works. |
|
|
|
Post by dreamboatcruise on Jan 27, 2018 21:52:40 GMT -5
Even if one believes progress will create enough confidence that equity financing will be possible, the magnitude of the resulting dilution would be quite hard to bound. How far in advance do you suspect MNKD will need to raise funds in order to extend their runway from 2nd quarter of 2018 onward? I assume it will need to be very soon and I'm not certain if progress on that aspect will necessarily be announced at the upcoming NobelCon14 meeting. Whenever it is, it would be best if it followed either 1) major news that will increase the PPS enough to make dilution more palatable or 2) upfront money from a partnership. My concern is that neither of these will transpire and dilution at around current PPS levels will be necessary. Perhaps the most ideal time for scenario 2 to have occurred is likely around the time of the FDA label change. Therefore, I think scenario 1 is the more likely path to further funding at this time, however what exactly that will entail is unknown. The consensus is that the STAT study results won't be released until the ADA meeting, which would be too late. The only other major catalyst that I can think of is a significant improvement in insurance coverage and/or increase in script #'s. MNKD seems to have less influence on improving insurance coverage. On the other hand, if it's true that script #'s should benefit 3-6 months following the launch of the new commercialization efforts (TV ads) in Q4 of 2017, then we should start to see an increase in script #'s right around the time when the company will definitely need to raise more capital. What are your thoughts on this? I wouldn't hazard a guess. Perhaps we will get some insight from Monday's call. I do wonder whether we'll get some insight into Q4 cash flow then. |
|
|
|
Post by mnholdem on Jan 28, 2018 8:10:00 GMT -5
Could also be announcement of IND filing for pulmonary hypertension drug. Expanding the perception of MannKind Corporation would be a very good thing. I noticed that management is beginning to market the company (e.g. recent engineering video) and Technosphere. I read once that most partnerships don't happen before FDA acceptance of a new drug IND.  |
|
|
|
Post by digger on Jan 28, 2018 11:18:17 GMT -5
Could also be announcement of IND filing for pulmonary hypertension drug. Expanding the perception of MannKind Corporation would be a very good thing. I noticed that management is beginning to market the company (e.g. recent engineering video) and Technosphere. I read once that most partnerships don't happen before FDA acceptance of a new drug IND. As I recall, Mannkind has a couple of companies out beating the bushes for deals. Has the company reported any progress from those efforts? |
|
|
|
Post by cjm18 on Jan 28, 2018 13:48:30 GMT -5
Mikes words...We expect to be filed in 50% of the worlds population this year.
That must include China to reach 50% . Maybe some of the 140m shares will be for the partner to raise capital.
|
|
|
|
Post by sellhighdrinklow on Jan 28, 2018 21:26:49 GMT -5
Somehow, some way, MNKD got themselves in so much debt that the other BP know this, saturate the message boards and on line media, chats, etc w negativity until they can buy MNKD for pennies on the $100 of true value while at the same time paying the endos not to prescribe Afrezza w their kickbacks on their current meal time insulin.
True?
|
|
